Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBerate-HR phase 3 trial of lerodalcibep for additional LDL-C lowering in high cardiovascular risk patients
MOH_2021-10-06_010297Phase 3Completed
- Sponsor
- LIB Therapeutics, LLC
- Start
- Sep 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypercholesterolemia, familial hypercholesterolemia (FH) and cardiac morbidity comparing Lerodalcibep with Placebo (2 arms). Primary endpoints: Percent reduction in calculated LDL-C at Week 52 and Average percent reduction in calculated LDL-C at Weeks 50 and 52. Started Sep 2021; status: completed.
02
Drugs
lerodalcibep
03
Conditions
hypercholesterolemiafamilial hypercholesterolemia (FH)cardiac morbidity
Beyond the preview
Go deeper on MOH_2021-10-06_010297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-10-06_010297.